Toronto Research Chemicals Inc.

Dactinomycin

• Category :

  Pharmaceuticals and Biochemicals

• Synonyms :

  3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-;hbf 386;Lyovac cosmegen;Meractinomycin;Oncostatin K;X 97;Actactinomycin A IV;Actinomycin 7;Actinomycin AIV;Actinomycindioic D acid, dilactone;Actinomycin C1;actinomycin cl;Actinomycin D;(-)-actinomycin d;actinomycin i;Actinomycin I1;Actinomycin IV;Actinomycin-[threo-val-pro-sar-meval];Actinomycin X 1;actinomycin x i;actinomyein-theo-val-pro-sar-meval;ACTO-D;AD;Dilactone actinomycindioic D acid;Dilactone actinomycin D acid;C1;Cosmegen;Dactinomycin D;dactinomyein d;2-amino-4,6-dimethyl-3-oxo-N,N'-bis[2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide;2-amino-4,6-dimethyl-3-oxo-N,N'-bis[2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxooctadecahydrocyclopenta[i][1,4,7,13]oxatriazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide;2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide;ACTD;

• CAS NO :

  50-76-0

• EC NO :

  200-063-6

• Molecular Formula :

  C₆₂H₈₆N₁₂O₁₆

• Molecular Weight :

  1255.417

• Main Specifications :

• InChI :

  InChI=1/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

• Molecular Structure :